26P Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to cabozantinib (CABO) plus durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the phase II ARCADIA trial)
Huber, V., Mereu, A., Lalli, L., Salsetta, J., Banfi, C., Squarcina, P., Sgambelluri, F., Mortarini, R., Stellato, M., Raggi, D., Guadalupi, V., Claps, M., Ferrari Bravo, W., Calareso, G., Alessi, A., Anichini, A., Procopio, G., Necchi, A., Rivoltini, L., Giannatempo, P.
Published in Immuno-oncology technology (01.12.2023)
Published in Immuno-oncology technology (01.12.2023)
Get full text
Journal Article